|
ADAM17
|
Lymph nodal metastasis/Loco-regional relapse
|
IHC/WB
|
50/46/Up
|
None
|
|
CD44
|
OS/DFS
|
IHC
|
138/59/Down
|
None
|
|
E-cadherin
|
Recurrence/OS
|
IHC
|
50/20/Up 112/59/Down
|
None
|
|
EGFR
|
OS
|
IHC
|
109/73/Up 59/58/Up
|
None
|
|
Estrogen-R2
|
OS
|
IHC/nPCR + sequencing
|
67/51/Up
|
Laryngeal/hypopharingeal cancer
|
|
FHIT
|
OS/DFS
|
IHC
|
53/61/Down
|
None
|
|
GLUT1
|
OS
|
IHC
|
40/26/up
|
Poor radiation response
|
|
HIF1A
|
OS/DFS
|
IHC
|
85/63/Down
|
None
|
|
Keratin-18
|
OS
|
IHC
|
308/54/Up
|
None
|
|
Keratin-8
|
OS
|
IHC
|
308/54/Up
|
None
|
|
Laminin γ2
|
DSS
|
DNA Microarray
|
119/NS/Up
|
None
|
|
MCM5
|
OS
|
IHC
|
97/61/Up
|
None
|
|
MET
|
OS
|
IHC
|
69/82/Up
|
None
|
|
Moesin
|
OS
|
IHC
|
103/NS/Up
|
Cytoplasmic expression pattern
|
|
Mucin-1
|
OS/DFS/Lymphnodal metastasis
|
IHC
|
206/39/Up
|
Within 5-years follow-up
|
|
Mucin-4
|
OS/DFS/Lymphnodal metastasis/Loco-regional relapse
|
IHC
|
150/41/Up
|
Within 5-years follow-up
|
|
p21
|
OS
|
IHC
|
192/71/Down
|
None
|
|
p27
|
DFS
|
IHC
|
192/80/Down
|
Only in patients with lymphnodal infiltration
|
|
p57
|
OS
|
IHC
|
67/87/Down
|
None
|
|
p63
|
OS
|
IHC
|
62/NS/Up
|
None
|
|
P-cadherin
|
Disease recurrence/Loco-regional relapse/OS
|
IHC
|
50/20/Down 67/45/Down 108/16/Down
|
None
|
|
Podoplanin
|
DSS
|
IHC
|
35/56/Up
|
None
|
|
Rb
|
DFS
|
IHC
|
220/49/Down
|
Only in p53+/pRb− patients
|
|
RUNX3
|
OS
|
IHC/WB
|
108/46/Down
|
None
|
|
S100A2
|
DFS/Cervical metastasis
|
RT-PCR + seq/IHC
|
135/26/Down 52/NS/Down
|
Nuclear expression pattern
|
|
SPARC
|
OS/DFI
|
DNA Microarray/IHC
|
62/NS/Up
|
None
|
|
STAT1
|
OS
|
IHC
|
89/NS/Up
|
None
|
|
Survivin 3α
|
OS
|
RT-PCR
|
97/NS/Up
|
Only in lymphnodes
|
|
TERT
|
OS
|
IHC
|
62/NS/Up
|
None
|
|
Ezrin
|
OS
|
IHC
|
47/85/Up
|
Cytoplasmic expression pattern
|
